Agenus shared a post on LinkedIn:
“BOT/BAL continues to redefine what’s possible in immunotherapy—durable survival across multiple tumor types, regulatory progress, and growing access for patients.
Read more on our Q3 2025 milestones.”
More posts featuring Agenus.